Reports on the impact of a study on the association of analgesic ibuprofen administration with increased risk of breast cancer on the plans of GlaxoSmithKline to purchase the healthcare division of Boots Healthcare International, which markets ibuprofen as Nurofen. Statement of Jean-Pierre Garnier, CEO of GlaxoSmithKline, regarding the plans of the company; Sales of Boots for its financial year ended March 31, 2005.